12 February 2008: The Biosafety Advisory Council issues a positive advice (with conditions) for this trial.
File:
Trial reference:
MI-CP178: Study of a Live, Attenuated Intranasal Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to < 24 Month-Old Children and in 2 Month-Old Infants